Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 801 results for "eisai"

Eisai to supply generic drug makers with bulk ingredients
Nikkei Asian Review

Eisai doubling its Indian API to ride Japan's generic wave

Active ingredient production facility at Eisai India plant--Courtesy of Eisai Japan's government is looking to procure more generic drugs to help relieve its healthcare budget, and Eisai intends to cash in on that shift by offering its own ... FiercePharmaManufacturing, 2 days ago
Japan's Eisai surprises with API move FiercePharma, 4 days ago

16 images for eisai

Watch List News, 4 days ago
American Banking News, 1 week ago
Nikkei Asian Review, 4 days ago
Drug Development Technology, 2 days ago
Contract Pharma, 3 days ago
Contract Pharma, 3 days ago
Venture Capital Post, 2 weeks ago
Monthly Prescribing Reference, 2 weeks ago
European Pharmaceutical Review, 2 weeks ago
OncLive, 3 weeks ago
Drug Development Technology

Halaven (eribulin mesylate) for the Treatment of Advanced Liposarcoma

Halaven (eribulin mesylate) is an injectable chemotherapy drug developed by Eisai for the treatment of unresectable or metastatic liposarcoma patients that previously received anthracycline-based chemotherapy. Eisai submitted the new drug ...
 Drug Development Technology2 days ago FDA Approves Eribulin Mesylate (Halaven) for Liposarcoma  Pharmscope2 weeks ago FDA clears Eisai's eribulin mesylate for rare type of soft tissue cancer  Seeking Alpha2 weeks ago Eisai grabs an FDA approval for life-extending soft tissue cancer drug  BioPharma Dive2 weeks ago
[x]  

Eisai in-licenses rights to Huya cancer compound

Japanese drug major Eisai (TYO: 4523) saw its shares leap 7.2% to 7,774 yen yesterday, after it revealed it has entered into an exclusive license agreement with Chinese pharma company Huya Bioscience International to develop and market the oral ...
 Pharma Letter1 week ago FDA approves Eisai's drug Halaven for type of soft tissue cancer  Yahoo! Finance2 weeks ago Eisai's Halaven gets FDA approval for soft tissue sarcoma  Pharma Letter2 weeks ago CORRECTED-FDA approves Eisais drug Halaven for type of soft tissue cancer (Jan. 28)  Reuters2 weeks ago
[x]  
European Pharmaceutical Review

EISAI : Phase III Trial Results of Eisai's Anticancer Agent Halaven(R) in Soft Tissue Sarcoma Published in The Lancet

- (ACN Newswire) - Eisai Co., Ltd. announced today that the results of a Phase III clinical study (Study 309) of its in-house discovered and developed anticancer agent Halaven(R) (eribulin mesylate) in patients with locally advanced, recurrent or ...
 4 Traders1 day ago Phase III Trial Results of Eisai's Anticancer Agent Halaven(R) in Soft Tissue Sarcoma Published in The Lancet  Benzinga.com1 day ago Phase III Trial Results of Eisais Anticancer Agent Halaven(R) in Soft Tissue Sarcoma Published in The Lancet  BizWire Express1 day ago 2/8/16 - FDA Approves Eisai's Halaven® eribulin mesylate Injection for the Treatment of Patients with Advanced Liposarcoma  Pharmacy Choice5 days ago
[x]  

Morphotek Announces Collaboration With Mayo Clinic On Phase II Trial

Exton, PA /PRNewswire/ - Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it is collaborating with researchers Keith L. Knutson, Ph.D. in the Department of Immunology and Edith A. Perez, M.D. in the Department of Hematology and ...
 Bioresearch Online1 week ago Morphotek collaborates with Mayo Clinic to apply its FRA diagnostic assays in phase II trial in triple-negative breast cancer  PharmaBiz1 week ago Morphotek Inc. Announces Collaboration With Mayo Clinic To Apply Its Folate Receptor Alpha Diagnostic Assays In A Phase II Clinical Trial In Triple-Negative Breast Cancer  BioSpace1 week ago
[x]  

Esteve to market Eisai's Fycompa in Spain

Japanese drug major Eisai (TYO: 4523) has entered into a new agreement with Spain's Esteve to co-promote Fycompa (perampanel) in Spain from February 2016. No financial details of the accord were disclosed. Eisai and Esteve will launch the new ...
 Pharma Letter1 week ago EISAI : Enters into Agreement with Esteve  4 Traders1 week ago Eisai, Esteve sign deal to co-promote anti-epilepsy drug Fycompa in Spain  Pharmaceutical Business Review1 week ago Eisai and Esteve Sign New Agreement to Co-promote Anti-epilepsy Drug Fycompa® (Perampanel) in Spain  Sys-Con Media1 week ago
[x]  

Global GERD Market Growth of 2.85% (2016-2020) - Key Vendors are AstraZeneca, Eisai, GlaxoSmithKline, Takeda, Johnson & Johnson

DUBLIN, Feb. 3, 2016 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/vkqjh2/global_gerd) has announced the addition of the "Global GERD Market 2016-2020" report to their offering. The report forecast that the ...
 TickerTech.com1 week ago
[x]  

Eribulin Mesylate (Halaven) Succeeds in Late-Stage Liposarcoma Trial

Positive results from a pivotal phase III study investigating the use of eribulin mesylate injection (Halaven, Eisai, Inc.) in certain types of soft-tissue sarcoma have been published online in the Lancet. The study evaluated overall survival (OS, ...
 PT Community1 day ago

Eisai Deal A Milestone On HUYAs Evolving Road

Taking off your underwear is liberating. Your balls can finally breathe! So it's easy to see why some guys want to feel that freedom all the time. In fact, there isn't any medical reason that states you need underwear for support, says Jamin ...
 MyInforms1 day ago
Contract Pharma

EISAI : HUYA Bioscience International Grants An Exclusive License For HBI-8000 In Japan And Other Asian Countries To Eisai

By a News Reporter-Staff News Editor at Pharma Business Week -- HUYA Bioscience International (HUYA) President, CEO, Executive Chairman & Founder Dr. Mireille Gillings announced that Eisai Co., Ltd. has acquired from HUYA an exclusive license ...
 4 Traders1 day ago Eisai Acquires License from Huya Bio  Contract Pharma3 days ago Eisai Acquires License from HUYA to Develop and Market HDAC Inhibitor in Asia  PharmaAsia2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - eisai
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less